Entero Healthcare Q3 FY26 Results: Strong Consolidated Growth, Margin Stability & Strategic Reset

Entero Healthcare Q3 Results show strong revenue growth and stable margins. The company reported a 25.57% year-on-year increase in revenue. At the same time, profitability remained steady despite an exceptional loss during the quarter.

Overall, the business continues to expand. However, margin levels remain thin, which means execution must stay strong.

Entero Healthcare Q3 Results – Revenue Analysis

Revenue for Q3 FY26 stood at ₹1,706.52 crore. This compares to ₹1,359.00 crore in Q3 FY25. Therefore, the company delivered 25.57% annual growth.

On a sequential basis, revenue increased 8.63% from ₹1,570.95 crore in Q2 FY26. This shows that growth is not slowing down.

Moreover, the nine-month revenue trend also remains strong. As a result, the company appears to be gaining market share in healthcare distribution.

In addition, demand in the healthcare supply chain remains stable. This supports consistent top-line expansion.

EBITDA and Margin Performance in Entero Healthcare Q3 Results

EBITDA for the quarter was ₹67.77 crore. Compared to ₹50.01 crore last year, this represents 35.51% growth.

Meanwhile, EBITDA margin improved to 3.97%. Last year, the margin was 3.68%. Although the improvement is small, it signals better cost control.

Furthermore, sequential margin improvement was also visible. This suggests operating leverage is slowly improving.

However, the business remains a low-margin model. Even small cost pressures can impact profit.

Profit Trends in Entero Healthcare Q3 Results

Profit After Tax stood at ₹33.88 crore. This is higher than ₹29.45 crore last year. Therefore, PAT grew 15.04% year-on-year.

However, on a quarter-on-quarter basis, PAT declined by 7.44%. The drop happened mainly because of higher tax and exceptional loss.

After adjusting for minority interest, profit attributable to shareholders was ₹27.63 crore. Although this shows annual growth, the sequential dip needs monitoring.

In short, profitability is stable but not accelerating sharply.

Impact of Exceptional Items

During the quarter, the company reported an exceptional loss of ₹8.17 crore. This was mainly due to new labour code adjustments.

Because this is regulatory in nature, it may not repeat every quarter. Nevertheless, investors should monitor such charges carefully.

Frequent exceptional items can reduce earnings visibility. Therefore, consistency will be important in upcoming quarters.

Standalone vs Consolidated Performance

Standalone revenue declined compared to last year. In contrast, consolidated revenue increased sharply.

This means growth is driven mainly by subsidiaries. Consequently, the group structure plays an important role in performance.

Additionally, consolidated PAT rose to ₹338.78 million from ₹294.48 million last year.

Overall, the company is evolving as a platform business rather than a single-entity operation.

Acquisition Cancellation – Strategic Decision

The board cancelled the acquisition of Khera Medisolutions and AV Medisolutions.

Although acquisitions can accelerate growth, they also bring integration risk. In this case, management chose capital discipline over aggressive expansion.

As a result, balance sheet risk may reduce in the short term.

Risks in Entero Healthcare Business Model

Despite strong growth, several risks remain.

First, margins are thin. Even small disruptions can impact earnings.

Second, working capital requirements are high. Distribution businesses require efficient inventory management.

Third, regulatory changes can affect cost structure. The recent labour code impact is an example.

Therefore, investors should track cash flow and margin trends closely.

Valuation Perspective

The company’s market capitalization is around ₹4,946 crore.

Based on annualized earnings, valuation appears moderate to premium. Consequently, future growth must remain strong to justify this level.

If margins expand further, valuation comfort may improve. Otherwise, the stock may move in line with earnings growth.

Future Outlook

Looking ahead, healthcare demand remains steady. Moreover, distribution networks are expanding across India.

If the company maintains revenue growth above 20%, operating leverage may improve further.

However, margin expansion will be the key factor to watch.

Overall, Entero Healthcare Q3 Results show growth momentum. At the same time, risk management remains important.

1️⃣ Executive Summary

Key Highlights – Q3 FY26

• Revenue: ₹1,706.52 Cr (▲ 25.57% YoY | ▲ 8.63% QoQ)
• EBITDA: ₹67.77 Cr (▲ 35.51% YoY | ▲ 9.18% QoQ)
• EBITDA Margin: 3.97% (expansion YoY)
• PAT: ₹33.88 Cr (▲ 15.04% YoY | ▼ 7.44% QoQ)
• PAT (After Minority Interest): ₹27.63 Cr
• Exceptional Loss: ₹8.17 Cr (new labour code impact)
• ESOP Grant: 5,000 options at ₹804
• Proposed acquisitions cancelled
• IPO proceeds fully utilized

Market Cap: ₹4,946 Cr (approx.)

2️⃣ Revenue Analysis – Growth Momentum Intact

Consolidated Revenue

What This Means

• 25%+ YoY growth indicates strong demand across distribution and healthcare supply chains.
• 8.63% sequential growth shows operational momentum.
• The company continues to scale its network-driven healthcare distribution model.

This growth signals increasing market penetration and improved client onboarding.

Standalone vs Consolidated – Important Insight

Standalone Q3 Revenue: ₹106.7 Cr
Consolidated Q3 Revenue: ₹1,706 Cr

Standalone performance declined, but consolidated numbers surged.

Interpretation:

• Growth is driven largely by subsidiaries and acquisitions.
• The core standalone entity is not the growth engine.
• Consolidated strength reflects integration of business units.

This suggests Entero is building a platform model rather than a single-entity business.

3️⃣ EBITDA & Margin Expansion

EBITDA Performance

Observations:

• 35.51% YoY EBITDA growth
• Margin expansion of 29 bps YoY
• Operating leverage starting to show

Despite being a low-margin business, the company managed to improve margins slightly. In distribution-led models, even small margin expansion matters significantly.

This is a positive signal.

4️⃣ Profitability – Mixed but Stable

PAT Analysis

Sequential decline due to:

• Higher tax outgo
• Exceptional loss of ₹8.17 Cr
• Lower other income

After Minority Interest

PAT attributable to shareholders: ₹27.63 Cr
YoY growth: +8.63%
QoQ decline: –12.56%

What Investors Should Note

• Core profitability trend is stable.
• Exceptional impact is non-recurring.
• Margin profile remains thin (~2%).

Thin margins make execution critical.

5️⃣ Exceptional Items – Should Investors Worry?

Exceptional Loss: ₹8.17 Cr (Consolidated)

Reason: Impact of new labour codes

This appears regulatory in nature and not operational weakness.

However:

• Frequent exceptional charges reduce earnings predictability.
• Investors must monitor if this repeats.

Currently, it does not indicate structural weakness.

6️⃣ Strategic Decision: Cancellation of Acquisitions

The board cancelled acquisition of:

• Khera Medisolutions Pvt Ltd
• AV Medisolutions Pvt Ltd

Reason: Commercial considerations

Why This Matters

• Shows capital discipline.
• Company avoided potentially value-destructive deal.
• Focus shifts to organic consolidation.

In distribution-heavy businesses, integration risk is high. Avoiding poor acquisitions is positive long-term.

7️⃣ ESOP Grant – Minor Dilution Impact

5,000 ESOPs granted at ₹804.

At current scale, dilution impact is negligible.

But signals:

• Management incentive alignment
• Retention strategy
• Confidence in growth trajectory

8️⃣ IPO Proceeds Fully Utilized

As of December 31, 2025:

IPO funds are fully deployed.

Implication:

• Expansion phase executed.
• Future growth will depend on internal cash flow or debt.
• Monitoring cash conversion cycle becomes critical.

9️⃣ Industry Positioning

Entero operates in healthcare distribution — a high-volume, low-margin sector.

Key characteristics:

• Stable demand
• Essential services
• Low pricing power
• High working capital

Compared to peers:

• Growth rate is competitive.
• Margin profile is typical.
• Scalability depends on logistics efficiency.

Long-term moat depends on:

• Network strength
• Vendor relationships
• Technology integration
• Working capital discipline

🔟 Risks Investors Must Consider

1. Thin Margins

2–4% EBITDA margins leave little room for error.

2. Working Capital Stress

Distribution businesses can face liquidity pressure.

3. Acquisition Integration Risk

Past growth driven by consolidation.

4. Regulatory Changes

Labour code impact shows regulatory sensitivity.

5. Minority Interest Impact

Profit attributable to shareholders grows slower than consolidated PAT.

1️⃣1️⃣ 9M FY26 Performance Snapshot

• Consolidated Revenue: ₹4,681.28 Cr
• Consolidated PAT: ₹100.71 Cr
• Strong double-digit growth trend maintained

Indicates sustained momentum, not just one-quarter spike.

1️⃣2️⃣ Financial Quality Check

Positive Signals:

• Revenue acceleration
• Margin expansion
• EBITDA growth > revenue growth
• Capital discipline (cancelled acquisition)

Neutral Signals:

• Sequential PAT dip
• Low margin business model

Negative Signals:

• Standalone weakness
• Exceptional losses

Overall quality: Moderate to improving

1️⃣3️⃣ Valuation Perspective

With Market Cap around ₹4,946 Cr:

Trailing PAT (approx annualized): ~₹135 Cr

Implied P/E: ~36–38x range

For a distribution business, this valuation assumes:

• Continued 20%+ growth
• Margin stability
• No working capital shocks

Investors must evaluate growth sustainability.

1️⃣4️⃣ Future Outlook

Growth Drivers:

• Healthcare demand
• Network expansion
• Operating leverage
• Technology adoption

Watch Factors:

• Debt levels
• Cash flow conversion
• Inventory management
• Acquisition strategy

If EBITDA margin expands above 4.5%, valuation comfort improves.

1️⃣5️⃣ Long-Term Investment Thesis

Entero Healthcare Q3 FY26 Results show:

• Strong revenue momentum
• Controlled margin expansion
• Strategic discipline
• Stable profitability

But:

• Business remains low-margin
• Execution risk high
• Valuation not cheap

This is a scale story, not a margin story.

📌 Final Verdict

Entero Healthcare Q3 FY26 Results indicate a company in scaling mode with improving operational discipline. Revenue momentum is strong. Margin expansion is gradual. Strategic decisions show maturity.

However, thin margins demand flawless execution.

For long-term investors, the key monitorables remain:

• Margin expansion
• Cash flow health
• Working capital discipline
• Acquisition quality

If managed well, Entero can evolve into a dominant healthcare distribution platform.

⚠️ Disclaimer

This content is for educational purposes only and not financial advice. Please do your own research before investing.

Disclaimer

This article is for educational purposes only. It is not investment advice. Please consult a financial advisor before investing.

Disclaimer: This article is for educational purposes only and not financial advice. Investors should do their own due diligence before investing.

Disclaimer: The projections of potential returns are based on current market conditions and company performance. Actual results may vary due to various factors, including market dynamics, economic conditions, and changes in the competitive landscape. Investors should conduct their own research and consult with financial advisors before making investment decisions.

Multibagger Stocks breakout stocks

High-growth green investments

Solar Technology Analysis

SEBI Official Website

⚠️ Not SEBI Registered—just here to share insights | 🚫 No paid services—everything shared is entirely free! 🧠 Always Learning and excited to grow together in this journey of market exploration.

📲 Join Our Investor Communities

🔹 Join our Telegram Channel: Multibagger Hunts
🔹 Join our WhatsApp Channel: Click to Join
✅ Free access
✅ Instant alerts
✅ Curated research for serious investors

TwitterXWhatsAppThreadsTelegramFacebookLinkedInGmailEmailShare